Gastrointestinal cancer research : GCR最新文献

{"title":"Metastatic colon cancer presenting as pituitary mass.","authors":"Danny Issa, Swapna Thota, Timothy Spiro, Hamed Daw, Andres Chiesa, Abdo Haddad","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 5-6","pages":"152-5"},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849902/pdf/gcr152.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31932678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal cancer research official journal of the international society of gastrointestinal oncology contents of volume 6, issues 1-6 january-december 2013.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 5-6","pages":"160"},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849903/pdf/gcr160.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31932680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A giant rectal villous adenoma with a malicious intent.","authors":"Maen Aboul Hosn, Nafisa Abdel-Hafiez, Reham Abdel-Wahab, Abir Al-Ahmadie, Ahmad Antar, Haifaa Dbouk, Hassan El Farran, Mahmoud El-Sawy Mohamed, Khaled Rida, Deborah Mukherji, Eileen M O'Reilly, Julio Garcia-Aguilar, Ghassan K Abou-Alfa","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 5-6","pages":"144-9"},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849900/pdf/gcr144.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31932676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upcoming articles.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 5-6","pages":"159"},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849898/pdf/gcr159.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31932679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer.","authors":"Arti Parekh, Minh Tam Truong, Itai Pashtan, Muhammad M Qureshi, Neil E Martin, Omer Nawaz, Sandra Cerda, John Willins, Kevan L Hartshorn, Lisa A Kachnic","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Preoperative chemoradiotherapy (preopCRT) for locally advanced rectal cancer is associated with grade 3 or higher acute gastrointestinal (GI) toxicity. This study was conducted to determine whether intensity-modulated radiation therapy (IMRT) significantly reduces acute GI toxicity, compared to 3-dimensional conformal RT (3D-CRT) in preopCRT for rectal cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted of 48 patients treated between January 2002 and August 2010 with preopCRT for rectal cancer. 3D-CRT or IMRT was administered at a planned dose of 45-50.4 Gy to patients positioned prone on a bowel-displacement device. Data regarding patient and tumor characteristics, treatment, acute toxicity, and tumor response were collected. Comparisons of acute toxicity and treatment response between 3D-CRT and IMRT were performed with the Chi-square or Fisher's exact test.</p><p><strong>Results: </strong>There were no significant differences in radiation dose, median age, race, gender, stage, type of concurrent chemotherapy, pathologic complete response (pCR), or type of surgery (lower anterior or abdominal perineal resection) between 3D-CRT and IMRT. There was a significant reduction in grade 2 or higher GI toxicity (3D-CRT, 60.7%; IMRT, 30%; P = .036) and grade 2 or higher diarrhea (3D-CRT, 42.8%; IMRT, 10%; P = .014). Two patients who underwent 3D-CRT required a treatment break (grade 3 diarrhea and grade 3 dehydration). Radiation duration was significantly less (IMRT, 35 days; 3D-CRT, 39 days; P ≤ .0001). pCR rates were 16.7% for 3D-CRT and 21.4% for IMRT (nonsignificant [NS]); pCR+microscopic residual rates were 57.1% for IMRT and 27.8% for 3D-CRT (P = .093).</p><p><strong>Conclusion: </strong>Maximal bowel displacement with IMRT yields favorable acute GI toxicity and pathologic downstaging profiles, as compared to 3D-CRT in preoperative CRT for rectal cancer and warrants further prospective investigation.</p>","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 5-6","pages":"137-43"},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849901/pdf/gcr137.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31932675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma.","authors":"Volkan Cetin,&nbsp;Bilal Piperdi,&nbsp;Venu Bathini,&nbsp;William V Walsh,&nbsp;Shakeeb Yunus,&nbsp;Jennifer F Tseng,&nbsp;Giles F Whalen,&nbsp;Wahid Y Wassef,&nbsp;Sidney P Kadish,&nbsp;Thomas J Fitzgerald,&nbsp;Christine Mikule,&nbsp;Yuxia Wang,&nbsp;Steven R Grossman","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. A minority of patients present with localized disease and surgical resection still offers patients the only hope for long-term survival. Locally advanced pancreatic cancer is defined as surgically unresectable, but has no evidence of distant metastases. The purpose of this study is to evaluate the efficacy and safety of cetuximab in combination with gemcitabine and 5-FU along with radiation therapy in locally advanced non-resectable, pancreatic adenocarcinoma, using progression free survival as the primary end point.</p><p><strong>Methods: </strong>This was a prospective, single arm, open label pilot phase II study to evaluate the anti-tumor activity of gemcitabine (200 mg/m(2) per week) and cetuximab (250 mg/m(2) per week after an initial 400 mg/m(2) loading dose) with continuous infusion 5-FU (800 mg/m(2) over 96 hours) and daily concurrent external beam radiation therapy (50.4 Gy total dose) for six weeks (cycle 1) in patients with non-metastatic, locally advanced pancreatic adenocarcinoma. Following neoadjuvant treatment, subjects were re-evaluated for response and surgical candidacy with restaging scans. After resection, or also if not resected; subjects received further therapy with four 28-day cycles (cycles 2-5) of weekly gemcitabine (1000 mg/m(2)) and cetuximab (250 mg/m(2)) on days 1, 8, and 15.</p><p><strong>Results: </strong>Between 2006 and 2011, twenty-six patients were screened and eleven of them were enrolled in the study. Most common reasons for screen failures were having resectable disease, metastatic disease or co-morbidity. Ten patients were able to tolerate and complete cycle 1 of chemoradiotherapy. One patient stopped the study prematurely due to grade III diarrhea. All except this one patient received planned radiation therapy. The response evaluation after cycle 1 showed one Partial Response, eight Stable Disease and two Progressive Disease. Four patients subsequently underwent surgical resection of the tumor. All patients had R0 resections. There was one preoperative mortality due to multiple organ failure. Median progression free survival (PFS) for four resected patients was 9.0 months while for unresected patients median PFS was 7.1 months. Median overall survival (OS) for four resected patients was 47.4 months and for unresected patients median OS was 17.0 months. Most common adverse events were hematologic (27%). Only two patients developed grade 3 neutropenia. Most common treatment related non-hematologic adverse events were diarrhea (10 of 11), nausea (8 of 11) and skin rash (10 of 11 patients). Only 9.5% of all reported non-hematologic adverse events were grade 3 or higher.</p><p><strong>Conclusions: </strong>The combination of cetuximab, weekly gemcitabine and continuous infusion of 5-FU with radiotherapy was quite well tolerated with intriguing clinical benefit and survival results in carefully se","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 4 Suppl 1","pages":"S2-9"},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849911/pdf/gcrS2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31932673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of an Extraintestinal GIST Presenting as a Giant Abdominopelvic Tumor.","authors":"Cavit Cöl,&nbsp;Fahri Yilmaz","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 4","pages":"120-2"},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782876/pdf/gcr120.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40256913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs).","authors":"Jonathan Strosberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent clinical trials have led to significant advancements in treatment options for metastatic neuroendocrine tumors of the pancreas. Sunitinib and everolimus have been approved by the Food and Drug Administration for treatment of progressive pancreatic NETs based on phase III trial data demonstrating improvements in progression-free survival. Cytotoxic drugs such as temozolomide and capecitabine have been associated with high radiographic response rates; however data derives primarily from subset analysis of prospective trials and from retrospective series. During the next few years, randomized clinical trials are expected to provide more clarity on the role of somatostatin analogs and cytotoxic drugs. New studies are also evaluating biomarkers that will potentially allow for improved selection of drugs for specific tumor subtypes. </p>","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 4 Suppl 1","pages":"S10-2"},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849907/pdf/gcrS10.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31932672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bile duct involvement portends poor prognosis in resected gallbladder carcinoma.","authors":"Robert Eil,&nbsp;Paul D Hansen,&nbsp;Maria Cassera,&nbsp;Susan L Orloff,&nbsp;Brett C Sheppard,&nbsp;Brian Diggs,&nbsp;Kevin G Billingsley","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder cancer (GBC) carries an unfavorable prognosis with high mortality. This retrospective study was conducted to identify prognostic factors after resection of GBC, to assist in selecting appropriate surgical and adjuvant therapy.</p><p><strong>Methods: </strong>Sixty-two patients from two institutions were identified with GBC by pathology. In 25, the cancer was unresectable at presentation. The remaining 37 patients comprised the study population. Log-rank analysis was used to assess univariate association with disease-free survival (DFS) and disease-specific survival (DSS). Cox regression was used for multivariate analysis.</p><p><strong>Results: </strong>Median DFS and DSS were 22.6 and 28.5 months respectively, with a median follow-up of 44.2 months. On univariate analysis, bile duct (BD) involvement was significantly associated with decreased DFS (P ≤ .001) and DSS (P = .004). BD involvement was uniformly fatal. LN involvement was not significantly associated with DFS or DSS (P = .85, P = .54).</p><p><strong>Conclusions: </strong>All patients with BD involvement in our population died of the disease. The subset of patients with resectable GBC and BD involvement is a group that is at high risk for recurrence and should be treated as such. In our small population, preoperative and intraoperative methods evaluating BD involvement were unreliable.</p>","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 4","pages":"101-5"},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782874/pdf/gcr101.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40256908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer.","authors":"Haifa Dbouk,&nbsp;Hana Ajouz,&nbsp;Ali Shamseddine,&nbsp;Deborah Mukherji,&nbsp;Eileen M O'Reilly,&nbsp;Ali Haydar,&nbsp;David Kelsen,&nbsp;Mohamed Naghy,&nbsp;Mohamed Eloubeidi,&nbsp;Fadi Geara,&nbsp;Leonard Saltz,&nbsp;Ghassan K Abou-Alfa","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 4","pages":"115-7"},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782872/pdf/gcr115.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40256910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}